Candidiasis can be present as a cutaneous, mucosal or deep-seated organ infection, which
is caused by more than 20 types of Candida sp., with C. albicans being the most common …

The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

Fungi cause serious infections in the immunocompromised and debilitated, and the
incidence of invasive mycoses has increased significantly over the last 3 decades. Slow …

Objectives Recent increases in triazole resistance in Aspergillus fumigatus have been
attributed primarily to target site (cyp51A) mutations. A recent survey of resistant isolates in …

Cryptococcus neoformans is a haploid environmental organism and the major cause of
fungal meningoencephalitis in AIDS patients. Fluconazole (FLC), a triazole, is widely used …

Infections by opportunistic pathogenic fungi, especially Candida species, Cryptococcus
neoformans, and Aspergillus fumigatus, are a serious medical problem in …

Invasive fungal infections remain a major source of global morbidity and mortality, especially
among patients with underlying immune suppression. Successful patient management …

Infections by fungal pathogens such as Candida albicans and Aspergillus fumigatus and
their resistance to triazole drugs are major concerns. Fungal lanosterol 14α-demethylase …

Targeting lanosterol 14α-demethylase (LDM) with azole drugs provides prophylaxis and
treatments for superficial and disseminated fungal infections, but cure rates are not optimal …